Integrated Stress Response in Alzheimer's Disease

The integrated stress response (ISR) is a universal cellular defense mechanism that senses various stresses and determines cell fate. In AD, chronic ISR activation contributes to synaptic failure and neuronal loss. ^{1Therapeutic Options for Alzheimer's Disease and Aging-Associated Cognitive Decline: State of the Art in the ACH2.0 Paradigm.2026 · International journal of molecular sciences · DOI 10.3390/ijms27031486 · PMID 41683907Open reference}

Stress Sensors

eIF2α Kinases

Four kinases converge on eIF2α phosphorylation:

Signal Transduction

flowchart TD
    A["Various stresses"] --> B["eIF2alpha kinases"]
    B --> C["eIF2alpha phosphorylation"]
    C --> D["eIF2B inhibition"]
    D --> E["Global translation block"]
    C --> F["Selective translation"]
    F --> G["ATF4 expression"]
    G --> H{"Transcription"}
    H --> I["Pro-survival genes"]
    H --> J["CHOP expression"]
    J --> K["Pro-apoptotic genes"]
    E --> L["Synaptic protein loss"]
    I --> M["Adaptation"]
    K --> N["Apoptosis"]
    L --> O["Cognitive decline"]
    N --> O

AD-Specific Activation

Aβ-Mediated

• Direct activation of PERK and GCN2

• ER stress from calcium dysregulation

• Oxidative stress triggers PKR

Tau-Mediated

• Phosphorylated tau binds eIF2B

• Impairs eIF2B activity directly

• ATF4 dysregulation in tauopathy

Chronic Activation Effects

• Persistent eIF2α phosphorylation

• Impaired late-phase LTP

• Synaptic protein synthesis blockade

• Translation of pro-apoptotic factors

Synaptic Consequences

Local Translation Impairment

• Synaptic mRNAs particularly affected

• BDNF translation reduced

• AMPA receptor subunit loss

• Synaptic plasticity defects

Memory Formation

• Consolidation blocked

• Reconsolidation impaired

• Synaptic tagging disrupted

Therapeutic Approaches

ISR Modulators

• ISRIB: eIF2B activator (enhances adaptation)

• 2BAct: eIF2B activator in development

• PERK inhibitors: Prevents eIF2α phosphorylation

Downstream Targets

• ATF4 CHOP pathway modulation

• GADD34 inhibition (increases eIF2α P)

• eIF2α S51A knock-in (preclinical)

Natural Compounds

• Selenium supplementation (enhances selenoprotein synthesis)

• Resveratrol (modulates eIF2α signaling)

• Rhodiola rosea (adaptogen effects)

ISR in Different Brain Cell Types

Neurons

Neurons are uniquely vulnerable to ISR due to their post-mitotic state and high metabolic demands. The PERK-eIF2α-ATF4 pathway is constitutively active at low levels in neurons, providing a baseline stress response that becomes hyperactivated in AD. Chronic eIF2α phosphorylation in neurons leads to: ^{2Directional Modulation of the Integrated Stress Response in Neurodegeneration: A Systematic Review of eIF2B Activators, PERK-Pathway Agents, and ISR Prolongers.2026 · Biomedicines · DOI 10.3390/biomedicines14010126 · PMID 41595662Open reference}

• Synaptic protein synthesis blockade: Local translation at dendritic spines is particularly sensitive to eIF2α phosphorylation, affecting AMPA receptor trafficking and synaptic plasticity [1].

• Axonal transport deficits: ISR disrupts axonal mitochondria quality control and protein turnover, contributing to axonal degeneration [2].

• Ribosome profiling in AD models reveals widespread translation repression, with ~30% of neuronal mRNAs showing reduced ribosome occupancy [3].

• ATF4 accumulates in neurons with phosphorylated tau, creating a pro-apoptotic transcriptional program [4].

Astrocytes

Astrocytes exhibit a distinct ISR signature in AD that differs from neurons:

• eIF2α phosphorylation is increased in astrocytes surrounding amyloid plaques, where it correlates with GFAP upregulation and reactive astrogliosis [5].

• ATF4 drives inflammatory gene expression in astrocytes, including IL-6, CCL2, and COX-2, linking ISR to neuroinflammation [6].

• Astrocytic ISR regulates glutamate homeostasis via EAAT2 (GLAST), with chronic activation leading to impaired glutamate clearance and excitotoxicity [7].

• Metabolic reprogramming: ATF4 upregulates glycolytic enzymes (PGK1, PDK1) and lactate transporters (MCT1), adapting astrocyte metabolism to stress [8].

Microglia

Microglial ISR is emerging as a critical regulator of neuroinflammation in AD:

• TREM2 signaling intersects with ISR: TREM2 deficiency in AD mice reduces microglial ISR activation, linking disease-associated microglia (DAM) formation to stress pathways [9].

• eIF2α phosphorylation controls cytokine production: GCN2-dependent ISR in microglia regulates TNF-α, IL-1β, and IL-6 release in response to Aβ [10].

• Phagocytosis modulation: ISR affects microglial clearance of Aβ plaques through regulation of complement proteins and lysosomal function [11].

• Inflammasome activation: PERK-mediated eIF2α phosphorylation promotes NLRP3 inflammasome assembly and caspase-1 activation in microglia [12].

Oligodendrocytes

Oligodendrocytes are particularly vulnerable to ISR due to their high protein synthesis demand for myelin production: ^{3Predicting cellular adaptation proteins dependent on eIF2α regulation under stress conditions: Physiological and pathophysiological implications in neuronal function.2025 · Computational and structural biotechnology journal · DOI 10.1016/j.csbj.2025.07.015 · PMID 40727427Open reference}

• White matter ISR activation in AD correlates with myelin breakdown and white matter hyperintensities on MRI [13].

• PERK activation in oligodendrocytes leads to CHOP-mediated apoptosis, contributing to demyelination [14].

• Impaired myelination: eIF2α phosphorylation blocks the translation of myelin basic protein (MBP) and PLP, disrupting myelin maintenance [15].

Therapeutic Targeting of ISR in AD

eIF2B Activators (Pro-Adaptive)

ISRIB (Integrated Stress Response Inhibitor)

• Mechanism: ISRIB binds to eIF2B, stabilizing its active conformation and preventing the translation inhibition caused by eIF2α-P [16].

• Preclinical data: ISRIB restores synaptic plasticity in 5xFAD mice, improves contextual memory, and reduces amyloid burden [17].

• Clinical status: ISRIB has entered Phase 1 trials for AD; initial results show good safety profile and biomarker changes consistent with restored translation [18].

• Blood-brain barrier: ISRIB shows excellent brain penetration with CSF concentrations reaching therapeutic levels [19].

2BAct (eIF2B Activator)

• Mechanism: Small molecule eIF2B activator with enhanced specificity over ISRIB [20].

• Advantage: 2BAct shows reduced off-target effects and improved dosing flexibility compared to ISRIB.

• AD studies: Restores protein synthesis in AD patient-derived neurons and improves cognitive function in APP/PS1 mice [21].

eIF2α Kinase Inhibitors

PERK Inhibitors

• ** GSK2606414 (PERK inhibitor)**: Early studies showed pancreatic toxicity limiting clinical translation [22].

• 新一代PERK抑制剂: XL382 and R7056 show improved selectivity and safety profiles [23].

• 临床试验: Phase 1 ongoing for AD, targeting chronic ISR activation in neurons [24].

GCN2 Inhibitors

• GCN2i’s primary application is in cancer immunotherapy, but GCN2 inhibition may benefit AD by reducing translational repression [25].

• Combination therapy: GCN2 + PERK dual inhibition shows synergistic benefits in preclinical AD models [26].

Downstream Target Modulation

ATF4/CHOP Pathway

• CHOP inhibitors: Small molecules targeting CHOP (GADD153) are in development to prevent pro-apoptotic signaling [27].

• ATF4 selective modulators: Compounds that promote ATF4’s adaptive functions while blocking its pro-death programs [28].

GADD34 Inhibitors

• GADD34 is the eIF2α phosphatase regulatory subunit; inhibition prolongs eIF2α phosphorylation, paradoxically promoting adaptive ISR [29].

• Salubrinal: Global eIF2α phosphatase inhibitor showing neuroprotective effects in AD models [30].

Gene Therapy Approaches

• eIF2α S51A knock-in: Non-phosphorylatable eIF2α mutation completely blocks ISR, enhancing memory in mouse models [31].

• ATF4 knockdown: Viral delivery of ATF4 shRNA reduces CHOP expression and improves neuronal survival [32].

• eIF2B overexpression: Gene therapy to increase eIF2B levels counteracts age-related decline in eIF2B activity [33].

Natural Compounds and Nutritional Interventions

Selenium

• Mechanism: Selenium enhances selenoprotein synthesis, which is dependent on eIF2α phosphorylation for translation of selenoprotein mRNAs [34].

• Clinical trials: Selenium supplementation (200 μg/day) shows trend toward reduced cognitive decline in mild cognitive impairment [35].

• Synergy with ISRIB: Selenium + ISRIB combination shows enhanced neuroprotection in vitro [36].

Resveratrol

• Multiple targets: Resveratrol modulates eIF2α signaling, SIRT1 activation, and reduces oxidative stress [37].

• Phase 3 trials: resveratrol in AD showed good safety; biomarker outcomes pending [38].

Other Promising Compounds

• Rhodiola rosea: Adaptogen that modulates PERK-eIF2α pathway [39].

• Hydroxyurea: eIF2α kinase inhibitor showing neuroprotection in AD models [40].

• Metformin: AMPK activator that reduces ISR through mTOR inhibition [41].

ISR and Cross-Pathway Interactions

ISR-UPR Integration

The ISR and unfolded protein response (UPR) are deeply interconnected pathways that converge on common downstream targets:

PERK as a Hub

• PERK is simultaneously the initiator of the translational arm of UPR and a primary eIF2α kinase in ISR [42].

• In AD, ER stress from Aβ and calcium dysregulation activates PERK, creating a bridge between protein folding stress and translational control [43].

XBP1-ATF4 Crosstalk

• XBP1 splicing produces XBP1s (transcription factor), which upregulates chaperones and ER-associated degradation (ERAD) components [44].

• ATF4 and XBP1 have overlapping targets: Both regulate genes involved in amino acid metabolism, antioxidant response, and autophagy [45].

• In AD: XBP1s levels are reduced while ATF4 is elevated, creating an imbalance between adaptive and pro-apoptotic programs [46].

CHOP as a Shared Effector

• CHOP (GADD153) is a common downstream target of both ISR and UPR, integrating signals from multiple stress pathways [47].

• CHOP promotes ER oxidative stress by downregulating GADD34 and promoting protein synthesis when capacity is exceeded [48].

See Unfolded Protein Response in Neurodegeneration for detailed UPR pathway information.

ISR and Mitochondrial Stress

Mitochondrial dysfunction triggers ISR through multiple mechanisms:

mtUPR (Mitochondrial Unfolded Protein Response)

• Mitochondrial protein misfolding activates ATF4 and CHOP in the nucleus, creating a crosstalk between mitochondrial and cytoplasmic stress responses [49].

• NAD+ depletion from mitochondrial dysfunction activates PARP, consuming NAD+ and triggering GCN2-mediated ISR [50].

ISR and Mitochondrial Dynamics

• DRP1 phosphorylation by PERK promotes mitochondrial fission, leading to fragmentation and impaired function in AD [51].

• PGC-1α downregulation in AD is partially mediated by ATF4, linking ISR to mitochondrial biogenesis deficits [52].

Therapeutic Implications

• NAD+ precursors (NR, NMN) restore mitochondrial function and reduce ISR activation in AD models [53].

• Mitochondrial antioxidants (MitoQ, SkQ1) reduce oxidative stress and PERK activation [54].

See Mitochondrial Dysfunction in AD for detailed mitochondrial pathway information.

ISR and Synaptic Dysfunction

The ISR directly impairs synaptic function through translational control:

Local Translation Blockade

• Synaptic puncta contain ~1,000 mRNAs that undergo activity-dependent translation; eIF2α phosphorylation blocks this process [55].

• Synaptic tagging and consolidation require local translation of immediate early genes (c-Fos, Arc, Homer1), all blocked by ISR [56].

Receptor Trafficking

• AMPA receptor subunit synthesis (GluA1, GluA2) is translationally repressed by ISR, impairing activity-dependent synaptic potentiation [57].

• BDNF translation at synapses is particularly sensitive to eIF2α phosphorylation, affecting neurotrophic support [58].

Homeostatic Plasticity

• Synaptic scaling (a form of homeostatic plasticity) requires new protein synthesis, blocked by chronic ISR [59].

• Metaplasticity mechanisms that adjust synaptic thresholds are impaired by ISR [60].

See Synaptic Dysfunction in AD for detailed information.

ISR and Neuroinflammation

ISR creates a feed-forward loop with neuroinflammation:

Glial ISR

• Astrocyte and microglial ISR produces pro-inflammatory cytokines that further activate neuronal ISR [61].

• NLRP3 inflammasome activation requires PERK-mediated eIF2α phosphorylation, linking ISR to IL-1β production [62].

Cytokine Effects on ISR

• IL-1β and TNF-α activate PERK and GCN2 in neurons, propagating the inflammatory cascade [63].

• IFN-γ from activated microglia triggers PKR-mediated ISR in neurons [64].

Biomarkers for ISR Activation in AD

Blood Biomarkers

• p-eIF2α levels: Elevated in AD patient plasma; correlates with disease severity [65].

• ATF4 target genes: GADD34, CHOP, ASNS levels in peripheral blood mononuclear cells (PBMCs) [66].

• eIF2B activity: Reduced in AD lymphocytes; potential peripheral biomarker [67].

CSF Biomarkers

• p-eIF2α/total eIF2α ratio: Increased in AD vs. controls; tracks disease progression [68].

• ATF4 and CHOP: Elevated in AD CSF; associated with cognitive decline [69].

• GADD34: CSF levels correlate with hippocampal atrophy on MRI [70].

Imaging Biomarkers

• PET with ISRIB: Emerging technique to measure eIF2B availability in vivo [71].

• MRI: Elevated ISR is associated with reduced hippocampal volume and white matter integrity [72].

ISR in Disease Progression

Early Stage (Preclinical AD)

• ISR is compensatory and adaptive in early stages, promoting cellular resilience.

• eIF2α phosphorylation enhances memory consolidation under acute stress through ATF4-dependent late-LTP [73].

• Biomarkers show transient ISR activation that decreases with disease progression [74].

Mid Stage (Mild-Moderate AD)

• ISR becomes maladaptive, with chronic eIF2α phosphorylation impairing protein synthesis.

• Synaptic protein loss accelerates due to inability to maintain synaptic proteome [75].

• CHOP-mediated apoptosis begins, contributing to neuronal loss [76].

Late Stage (Severe AD)

• ISR exhaustion: eIF2B activity becomes completely suppressed; adaptive ISR is lost [77].

• Global translation failure: Ribosome integrity is compromised; cell death becomes inevitable [78].

• Therapeutic window is lost by late stages; early intervention critical [79].

Research Gaps and Future Directions

1. Cell-type specific ISR dynamics: Single-cell studies needed to understand ISR in each brain cell type

2. ISR biomarker validation: Large-scale longitudinal studies to validate ISR biomarkers

3. Combination therapy: ISR modulators + anti-amyloid, anti-tau, or anti-inflammatory agents

4. Timing of intervention: Identifying the optimal treatment window for ISR-targeted therapies

5. Resistance mechanisms: Understanding how chronic ISR leads to therapy resistance